|
|
Vaccine Detail
|
mAb PC61 and DC/tumor fusion |
| Vaccine Information |
- Vaccine Name: mAb PC61 and DC/tumor fusion
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007634
- Type: DC/tumor fusion vaccine
- Status: Research
- Immunization Route: Intramuscular injection (i.m.)
- Description: In this study, we sought to investigate whether functional inactivation of CD4+CD25+FoxP3+ Treg with anti-CD25 monoclonal antibody (mAb) PC61 prior to DC/tumor vaccination would significantly improve immunotherapy in the murine B16 melanoma model (Tan et al., 2013).
|
| Host Response |
|
Human Response
- Vaccine Immune Response Type: VO_0003057
- Immune Response: increase in cancer immunity was mediated by anti-tumor specific CD4+ T-helper cells, without concomitant induction of CD8+ cytotoxic T cells (Tan et al., 2013).
|
| References |
Tan et al., 2013: Tan C, Reddy V, Dannull J, Ding E, Nair SK, Tyler DS, Pruitt SK, Lee WT. Impact of anti-CD25 monoclonal antibody on dendritic cell-tumor fusion vaccine efficacy in a murine melanoma model. Journal of translational medicine. 2013; 11; 148. [PubMed: 23768240].
|
|
